<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819752</url>
  </required_header>
  <id_info>
    <org_study_id>CCR4325</org_study_id>
    <nct_id>NCT02819752</nct_id>
  </id_info>
  <brief_title>PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <acronym>PEACH</acronym>
  <official_title>Phase I Dose-escalation Study of PEmbrolizumab (MK3475) Anti-PD1 Immune Checkpoint Inhibitor Combined With Radical Chemoradiotherapy in Patients With Stage IV Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to establish whether the combination of pembrolizumab (MK-3475) and&#xD;
      conventional cisplatin-based chemoradiotherapy is tolerable and results in acceptable levels&#xD;
      of acute and late toxicity in patients with stage IV LA-SCCHN. In particular, the study will&#xD;
      provide data on the levels of mucosal and cutaneous toxicity within the radiation fields, as&#xD;
      these are the primary acute toxicities associated with this treatment regimen. In addition,&#xD;
      toxicity outside the radiation portals (which may theoretically be exacerbated by radiation)&#xD;
      will be studied. However, all toxicity will be monitored. This study will also give an&#xD;
      indication of the activity of pembrolizumab in LA-SCCHN because we are deliberately selecting&#xD;
      a group of patients with high- and intermediate-risk disease who have a significant chance of&#xD;
      experiencing loco-regional or systemic failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single centre phase 1 dose-escalation study to confirm the safety of combining&#xD;
      pembrolizumab with standard platin-based chemoradiotherapy in patients with stage IV high-&#xD;
      and intermediate-risk locally-advanced squamous cell carcinoma of the head and neck&#xD;
      (LA-SCCHN). 6-36 patients (18 HPV+ve and 18 HPV-ve) will be recruited in a standard 3+3&#xD;
      dose-escalation trial design with an expansion cohort at the maximum tolerated dose (or 200&#xD;
      mg, if no DLT is defined). A pre-loading dose of 100 or 200mg (dependent on dosing level) of&#xD;
      pembrolizumab will be given once the patient has completed the screening period. Patients&#xD;
      will then return 2 weeks later to begin cycle 1 of a regimen of pembrolizumab 3 weekly at a&#xD;
      dose of 100 or 200mg (dependent on dosing level) for a total of 7 cycles (3 during&#xD;
      chemoradiotherapy and 4 after chemoradiotherapy).&#xD;
&#xD;
      Parallel studies in HPV-ve and HPV +ve disease will be conducted (note these patients may&#xD;
      have different patterns of co-morbidity and, hence, different treatment-related toxicities).&#xD;
      The primary endpoint of the study will be safety and tolerability. Dose-limiting acute&#xD;
      toxicity will be assessed during administration of study drug according to CTCAEv4.0. The&#xD;
      maximum tolerated dose of study drug (or 200 mg in the absence of DLT) will be used in a&#xD;
      subsequent randomised phase 2 study comparing standard-of-care therapy with standard-of-care&#xD;
      therapy plus study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the maximum tolerated dose that can safely be combined with platin-based chemoradiotherapy in patients with HPV-ve and HPV+ve LA-SCCHN</measure>
    <time_frame>Six weeks after the completion of chemoradiotherapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute toxicity as measured during treatment by CTCAE v4.0</measure>
    <time_frame>Up until 6 weeks after the end of chemoradiotherapy (week 14 of the study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Progression Free Survival</measure>
    <time_frame>Six months, one year and two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Overall Survival</measure>
    <time_frame>Six months, one year and two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the duration of clinical benefit using RECIST</measure>
    <time_frame>Six months, one year and two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate late radiotherapy toxicities as measured during treatment by LENT SOMA</measure>
    <time_frame>52 weeks from the end of radiation therapy (week 7)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Identify biomarkers and correlate with clinical benefit, as defined by RECIST v1.1</measure>
    <time_frame>through study completion (24 months)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of circulating free tumour DNA</measure>
    <time_frame>Screening, week 3, week 9 and week 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Immunohistochemical analysis to identify immune infiltrates</measure>
    <time_frame>through study completion (24 months)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>HPV-ve stage IVA/IVB SCCHN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab and Chemoradiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPV+ve stage IVA/IVB SCCHN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab and Chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab</description>
    <arm_group_label>HPV+ve stage IVA/IVB SCCHN</arm_group_label>
    <arm_group_label>HPV-ve stage IVA/IVB SCCHN</arm_group_label>
    <other_name>MK-3475/pembrolizumab (KEYTRUDAÂ®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy - Standard Treatment</description>
    <arm_group_label>HPV+ve stage IVA/IVB SCCHN</arm_group_label>
    <arm_group_label>HPV-ve stage IVA/IVB SCCHN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Chemotherapy - Standard Treatment</description>
    <arm_group_label>HPV+ve stage IVA/IVB SCCHN</arm_group_label>
    <arm_group_label>HPV-ve stage IVA/IVB SCCHN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have treatment naive and histologically confirmed high-/intermediate-risk LA-SCCHN&#xD;
&#xD;
          2. Be willing and able to provide written informed consent for the trial.&#xD;
&#xD;
          3. Be &gt; or = 18 years of age on day of signing informed consent.&#xD;
&#xD;
          4. Have measurable disease based on RECIST 1.1.&#xD;
&#xD;
          5. Have provided tissue from an archival tissue sample or newly obtained core or&#xD;
             excisional biopsy of a tumour lesion.&#xD;
&#xD;
          6. Have a performance status of 0 or 1 on the ECOG Performance Scale.&#xD;
&#xD;
          7. Be fit for definitive platin-based chemoradiation therapy.&#xD;
&#xD;
          8. Demonstrate adequate organ function as defined in table 1, all screening labs should&#xD;
             be performed within 10 days of confirmation of study eligibility.&#xD;
&#xD;
          9. Female patient of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to confirmation of study eligibility. If the urine&#xD;
             test is positive or cannot be confirmed as negative, a serum pregnancy test will be&#xD;
             required.&#xD;
&#xD;
         10. Female patient s of childbearing potential should be willing to use 2 methods of birth&#xD;
             control or be surgically sterile, or abstain from heterosexual activity for the course&#xD;
             of the study through 120 days after the last dose of study medication (Reference&#xD;
             Section 6.7.2). Patient s of childbearing potential are those who have not been&#xD;
             surgically sterilized or have not been free from menses for &gt; 1 year.&#xD;
&#xD;
         11. Male patient s should agree to use an adequate method of contraception starting with&#xD;
             the first dose of study therapy through 120 days after the last dose of study therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is currently participating in or has participated in a study of an investigational&#xD;
             agent or using an investigational device within 4 weeks of the first dose of&#xD;
             treatment.&#xD;
&#xD;
          2. Has received prior radiotherapy to the head and neck region.&#xD;
&#xD;
          3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
          4. Has had a prior monoclonal antibody, chemotherapy, targeted small molecule therapy, or&#xD;
             radiation therapy.&#xD;
&#xD;
          5. Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin, or in situ cervical cancer that has undergone potentially curative therapy.&#xD;
&#xD;
          6. Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Patient s with previously treated brain metastases may participate&#xD;
             provided they are stable (without evidence of progression by imaging for at least four&#xD;
             weeks prior to the first dose of trial treatment and any neurologic symptoms have&#xD;
             returned to baseline), have no evidence of new or enlarging brain metastases, and are&#xD;
             not using steroids for at least 7 days prior to trial treatment.&#xD;
&#xD;
          7. Has an active autoimmune disease requiring systemic treatment within the past 3 months&#xD;
             or a documented history of clinically severe autoimmune disease, or a syndrome that&#xD;
             requires systemic steroids or immunosuppressive agents. Patient s with vitiligo or&#xD;
             resolved childhood asthma/atopy would be an exception to this rule. Patients that&#xD;
             require intermittent use of bronchodilators or local steroid injections would not be&#xD;
             excluded from the study. Patient s with hypothyroidism stable on hormone replacement&#xD;
             or Sjogren's syndrome will not be excluded from the study.&#xD;
&#xD;
          8. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.&#xD;
&#xD;
          9. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         10. Has active tuberculosis.&#xD;
&#xD;
         11. Has known hypersensitivity to pembrolizumab or any of its excipients.&#xD;
&#xD;
         12. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the patient's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the patient to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         13. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         14. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
         15. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or&#xD;
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including&#xD;
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation&#xD;
             or checkpoint pathways).&#xD;
&#xD;
         16. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
         17. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
         18. Has received a live vaccine within 30 days prior to the first dose of trial treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Kevin Harrington, CTU</last_name>
    <role>Study Director</role>
    <affiliation>Consultant Clinical Oncologist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Marsden Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell carcinoma</keyword>
  <keyword>squamous cell carcinoma of the head and neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

